Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2021 | Optimizing transplantation outcomes for patients with AML

Andreas Burchert • 15 Oct 2021
COSTEM 2021
Acute Myeloid Leukemia Leukemia Gilteritinib Ivosidenib Midostaurin Venetoclax

Andreas Burchert, MD, University of Marburg, Marburg, Germany, outlines the latest data on the optimization of transplantation outcomes for patients with acute myeloid leukemia. Dr Burchert describes how the risk of relapse currently presents the greatest challenge in the field and comments on the need to improve the rate and depth of remissions prior to transplantation. In the post-transplant setting, Dr Burchert highlights the need to have highly tolerable therapeutic options available. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Andreas Burchert

5:00
Post-transplant maintenance strategies in AML
Andreas Burchert • 15 Oct 2021
2:57
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert • 15 Oct 2021
2:23
Sorafenib for FLT3-ITD-positive AML
Andreas Burchert • 3 Dec 2018
1:44
The future of AML therapy
Andreas Burchert • 3 Jan 2019

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals